Stay updated with breaking news from Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shattuck Labs Inc (NASDAQ: STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m)
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance...
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ('Abbisko Therapeutics' hereafter) announced that two major clinical updates...
MARSEILLE, France--(BUSINESS WIRE)--Nov 3, 2023--
Innate Pharma SA announced that several abstracts, including one oral presentation, have been selected for the 65th ASH Annual Meeting and Exposition, taking place December 9-12, 2023 in San Diego,...